EVALUATION OF SERUM NITRIC OXIDE IN ESSENTIAL HYPERTENSION AND ITS CORRELATION WITH SEVERITY OF DISEASE

Authors

  • Sarthak Ranjan Nayak Assistant Professor
  • Itishri Jena
  • Pramila Kumari Mishra
  • Sudeshna Behera
  • Subhashree Ray

DOI:

https://doi.org/10.22159/ajpcr.2016.v9s2.13464

Abstract

ABSTRACT
Objective: Hypertension is the most common cardiovascular disease and one of the most important public health concerns all over the world. Primary
or essential hypertension is the major form of arterial hypertension without any definitive cause. It results from increase vascular tone and resistance
which may be confined to the lower level of endothelial derived relaxing factor such as nitric oxide (NO). Hence, the objective of this study is to find
out whether any correlation exists between the concentrations of serum NO (nitrite) and essential hypertensive patients categorized according to the
Joint National Committee 7 classification.
Methods: We selected age- and sex-matched 24 healthy individuals as controls and 35 essential hypertensive patients as cases. Out of 35 cases, 24
were included in stage 1 and 11 in stage 2 of essential hypertension. We estimated serum NO levels in study groups basing on the principle of Griess
reaction.
Results: We observed reduction in mean serum NO level in cases which was statistically highly significant as compared to controls (8.14±0.33 vs.
13.53±0.38 µmol/L, p<0.001) and also in stage 2 patients when compared with stage 1 patients (5.97±0.31 vs. 9.15±0.28 µmol/L, p<0.001). In
hypertensive patients, serum NO showed a highly significant inverse correlation to both systolic (r=−0.89, p<0.001) as well as diastolic (r=−0.64,
p<0.001) blood pressure.
Conclusion: Thus, we can conclude that lower level of serum NO can be an important causative factor in the progress of essential hypertension.
Keywords: Essential hypertension, Endothelial-derived relaxing factor, Nitric oxide, Joint National Committee 7.

Downloads

Download data is not yet available.

References

REFERENCES

Park K. Hypertension. In: Park’s Textbook of Preventive and Social

Medicine. 23

ed. Jabalpur, (India): Banarsidas Bhanot Publishers;

p. 372-7.

th

Kotchen TA. Hypertensive vascular disease. In: Kasper DL, Fauci AS,

Braunwald E, Hauser SL, Longo DL, Jameson JL, Loscalzo J,

editors. Harrison’s Principle of Internal Medicine. 19

ed., Vol. II.

New York, NY: Mc Graw Hill Companies; 2015. p. 1611-26.

th

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA,

Izzo JL Jr, et al. Seventh report of the Joint National Committee on

prevention, detection, evaluation, and treatment of high blood pressure.

Hypertension 2003;42:1206-52.

Victor RG. Arterial hypertension. In: Goldman L, Schafer AI, editors.

Goldman-Cecil Medicine. 25

ed. Philadelphia, PA: Elsvier Publication;

p. 381-96.

th

Carretero OA, Oparil S. Essential hypertension. Part I: Definition and

etiology. Circulation 2000;101(3):329-35.

Staessen JA, Wang J, Bianchi G, Birkenhäger WH. Essential

hypertension. Lancet 2003;361(9369):1629-41.

Leiper J, Nandi M. The therapeutic potential of targeting endogenous

inhibitors of nitric oxide synthesis. Nat Rev Drug Discov

;10(4):277-91.

Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or

progression. Dependency on vascular nitric oxide. Arterioscler Thromb

Vasc Biol 1996;16(1):44-50.

Kelm M. Nitric oxide metabolism and breakdown. Biochim Biophys

Acta 1999;1411(2-3):273-89.

Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T,

Lüscher TF. Reduced endothelial nitric oxide synthase expression and

production in human atherosclerosis. Circulation 1998;97(25):2494-8.

Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric

dimethylarginine (ADMA) in endothelial dysfunction and

cardiovascular disease. Curr Cardiol Rev 2010;6(2):82-90.

Sena CM, Pereira AM, Seiça R. Endothelial dysfunction: A major

mediator of diabetic vascular disease. Biochim Biophys Acta

;1832(12):2216-31.

Bryan NS, Grisham MB. Methods to detect nitric oxide and its metabolites

in biological samples. Free Radic Biol Med 2007;43(5):645-57.

Ranasinghe P, Cooray DN, Jayawardena R, Katulanda P. The influence

of family history of hypertension on disease prevalence and associated

metabolic risk factors among Sri Lankan adults. BMC Public Health

;15:576.

Ruilope LM. The kidney as a sensor of cardiovascular risk in essential

hypertension. J Am Soc Nephrol 2002;13 Suppl 3:S165-8.

Ruilope LM, Lahera V, Rodicio JL, Romero JC. Participation of nitric

oxide in the regulation of renal function: Possible role in the genesis of

arterial hypertension. J Hypertens 1994;12(6):625-31.

Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al.

Primary prevention of hypertension: Clinical and public health advisory

from The National High Blood Pressure Education Program. JAMA

;288(15):1882-8.

Eliot WJ, Bakris GL, Black HR. Hypertension: Epidemiology,

pathophysiology, diagnosis, and treatment. In: Fuster V, Alexander RW,

Hurst JW, O’Rourke RA, King SB III

, Nash IS, et al., editors. In:

Hurst’s The Heart. 13

th

rd

ed. USA: McGraw-Hill; 2011. p. 1549-80.

Tobian L. Dietary sodium chloride and potassium have effects on the

pathophysiology of hypertension in humans and animals. Am J Clin

Nutr 1997;65 2 Suppl:606S-11.

Levine BE, Weller JM, Remington RD. Serum sodium and potassium in

essential hypertension. Circulation 1961;24:29-33.

Hvarfner A, Bergstrom R, Morlin C, Wide L, Ljunghall S. Relationships

between calcium metabolic indices and blood pressure in patients

with essential hypertension as compared with a healthy population.

J Hypertens 1987;5(4):451-6.

Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric

oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A

;86(9):3375-8.

Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reduced

plasma concentrations of nitrogen oxide in individuals with essential

hypertension. Hypertension 1997;30:405-8.

Arora S, Das N, Srivastava K. Nitric oxide and eNOS gene in essential

hypertension. Int J Collab Res Intern Med Public Health 2009;1(2):56-71.

Chandra M, Maurya DR, Kumar S, Basara H, Ghatak A, Tekwani BL,

et al. Reversible suppression of nitric oxide system in essential

hypertension. Indian J Clin Biochem 2003;18(2):150-3.

Published

01-10-2016

How to Cite

Nayak, S. R., I. Jena, P. Kumari Mishra, S. Behera, and S. Ray. “EVALUATION OF SERUM NITRIC OXIDE IN ESSENTIAL HYPERTENSION AND ITS CORRELATION WITH SEVERITY OF DISEASE”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 8, Oct. 2016, pp. 179-82, doi:10.22159/ajpcr.2016.v9s2.13464.

Issue

Section

Original Article(s)